A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-01-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancermetastaticsyndromemelanomaof study
  Phrases that lowered it: participantssolidreceipttumorsadvanced
• Trials the sponsor started in the prior 2 years: 102 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 5.7% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 1151 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 9.6% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 8 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 14029 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 80.1% (lowers risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) NCT03249792 · started 2017 · scored riskier than 42% of active trials terminated
• A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors NCT05091346 · started 2021 · scored riskier than 44% of active trials completed
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma NCT05093608 · started 2021 · scored riskier than 52% of active trials terminated
• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) NCT04740307 · started 2021 · scored riskier than 70% of active trials completed
• Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) NCT02702401 · started 2016 · scored riskier than 53% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.